A bright smile may be the first thing you notice about a person, but a closer look could reveal that their teeth are less than bright. The majority of Americans desire whiter teeth, and millions are spent each year on over-the-counter and in-office treatments to achieve this goal. As a result, many have wondered if…
Japan’s Shionogi Seeks Approval for COVID-19 Pill
TOKYO—Drugmaker Shionogi & Co. Ltd. has applied for approval to make and sell its oral COVID-19 treatment in Japan, the firm said on Friday. Known as S-217622, the drug would become the country’s third antiviral pill approved for coronavirus patients, following those developed by Pfizer Inc. and Merck & Co.. In a statement, Shionogi said…
Pfizer Says It Applied for Japan Government’s Approval for Oral COVID-19 Drug
January 14, 2022
admin
Asia & PacificBrightBusiness & EconomyCCP VirusCompaniesCOVID-19drugHealth NewsJapanMind & BodyOralPfizerWorld
0 Comment
TOKYO—U.S. drugmaker Pfizer Inc. said on Friday it has applied for Japanese government approval for its oral COVID-19 treatment. The application is based on global Phase II/III trials that Japan was part of, Pfizer said in a statement. With COVID-19 cases surging again, Japan is betting heavily on oral treatments to keep serious infections and…
How Much Revenue Could Pfizer’s Oral COVID-19 Pill Fetch?
Pfizer Inc. announced Wednesday its oral COVID-19 antiviral pill, Paxlovid, has been authorized for use by the U.S. Food and Drug Administration. Pfizer Analysts SVB Leerink analyst Geoffrey Porges has a Market Perform rating and a $52 price target for Pfizer. BofA Securities analyst Geoff Meacham maintained a Neutral rating and a $59 price target. Broad Label, Increased…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`